文献速递泌尿男性生殖肿瘤

局限期中危前列腺癌:短期雄激素抑制联合放疗剂量递增的12年EORTC 22991结果

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
PubMed 文献 · J Clin Oncol · 2021-07-26

EORTC 22991试验纳入481例中危局限期前列腺癌患者,随机接受单纯外照射放疗(EBRT,74或78 Gy)或EBRT联合6个月同期及辅助雄激素抑制(AS)。中位随访12.2年,EBRT+AS显著改善无事件生存(EFS)和无病生存(DFS),但无远处转移生存(DMFS)和总生存(OS)差异未达统计学显著。

要点

  • 中危局限期前列腺癌接受74或78 Gy EBRT时,联合6个月AS显著改善EFS和DFS。
  • 10年DMFS和OS在联合AS组数值上较高,但差异未达统计学显著。
  • 长期随访支持6个月同期及辅助AS作为中危患者联合剂量递增EBRT的标准选择。

核心结论

  • 6个月同期及辅助雄激素抑制可显著改善接受74或78 Gy EBRT的中危局限期前列腺癌患者的EFS和DFS。
  • 联合AS对DMFS和OS的影响未达到统计学显著差异。

研究设计与样本

  • EORTC 22991(NCT00021450)随机对照试验,819例患者随机分配至EBRT或EBRT+AS(从EBRT第1天开始)。
  • 本报告聚焦481例中危患者(UICC TNM 1997 cT1b-c或T2a且PSA≥10 ng/mL或Gleason≤7且PSA≤20 ng/mL,N0M0),其中342例(71.1%)计划74 Gy,139例(28.9%)计划78 Gy。
  • 主要终点EFS,按意向性治疗分析,依据EBRT剂量分层,双侧α=5%。

主要发现

  • 中位随访12.2年,EBRT+AS组245例中92例、单纯EBRT组236例中132例发生EFS事件,主要为PSA复发(48.7%)或死亡(45.1%)。
  • EBRT+AS显著改善EFS(HR=0.53;CI,0.41至0.70;P<.001)和DFS(HR=0.67;CI,0.49至0.90;P=.008)。
  • 10年DMFS:EBRT+AS组79.3%(CI,73.4至84.0),单纯EBRT组72.7%(CI,66.2至78.2),HR=0.74(CI,0.53至1.02;P=.065)。
  • 共140例死亡(EBRT+AS组64例,单纯EBRT组76例);10年OS:EBRT+AS组80.0%(CI,74.1至84.7),单纯EBRT组74.3%(CI,67.8至79.7),HR=0.74(CI,0.53至1.04;P=.082)。

临床怎么用

  • 对于接受74或78 Gy剂量递增EBRT的中危局限期前列腺癌患者,可考虑联合6个月同期及辅助雄激素抑制以改善EFS和DFS。
  • 与患者沟通时需说明DMFS和OS的获益未达统计学显著,需结合个体情况权衡。

局限性

  • DMFS和OS的差异未达统计学显著,可能存在随访时间或样本量限制。
  • 本报告仅针对中危患者亚组,结果外推至高危或其他剂量方案需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event- (EFS, Phoenix) and clinical disease-free survival (DFS) of intermediate- and high-risk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy. We report the long-term results in intermediate-risk patients treated with 74 or 78 Gy EBRT, as per current guidelines. PATIENT AND METHODS: Of 819 patients randomly assigned between EBRT or EBRT plus AS started on day 1 of EBRT, 481 entered with intermediate risk (International Union Against Cancer TNM 1997 cT1b-c or T2a with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≤ 7 and PSA ≤ 20 ng/mL, N0M0) and had EBRT planned at 74 (342 patients, 71.1%) or 78 Gy (139 patients, 28.9%). We report the trial primary end point EFS, DFS, distant metastasis-free survival (DMFS), and overall survival (OS) by intention-to-treat stratified by EBRT dose at two-sided α = 5%. RESULTS: At a median follow-up of 12.2 years, 92 of 245 patients and 132 of 236 had EFS events in the EBRT plus AS and EBRT arm, respectively, mostly PSA relapse (48.7%) or death (45.1%). EBRT plus AS improved EFS and DFS (hazard ratio [HR] = 0.53; CI, 0.41 to 0.70; P < .001 and HR = 0.67; CI, 0.49 to 0.90; P = .008). At 10 years, DMFS was 79.3% (CI, 73.4 to 84.0) with EBRT plus AS and 72.7% (CI, 66.2 to 78.2) with EBRT (HR = 0.74; CI, 0.53 to 1.02; P = .065). With 140 deaths (EBRT plus AS: 64; EBRT: 76), 10-year OS was 80.0% (CI, 74.1 to 84.7) with EBRT plus AS and 74.3% (CI, 67.8 to 79.7) with EBRT, but not statistically significantly different (HR = 0.74; CI, 0.53 to 1.04; P = .082). CONCLUSION: Six months of concomitant and adjuvant AS statistically significantly improves EFS and DFS in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bolla M, Neven A, Maingon P, et al. Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. J Clin Oncol. 2021. PMID: 34310202. doi:10.1200/JCO.21.00855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。